



## Clinical trial results:

**Protocol Title: A Multi-Center, Open-Label Study to Evaluate Safety, Efficacy and Pharmacokinetics of Belimumab Plus Standard Therapy in Chinese Paediatric Patients with Active Systemic Lupus Erythematosus (SLE)**

### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2025-000106-42 |
| Trial protocol           | Outside EU/EEA |
| Global end of trial date | 13 August 2024 |

### Results information

|                                |                |
|--------------------------------|----------------|
| Result version number          | v3 (current)   |
| This version publication date  | 16 July 2026   |
| First version publication date | 17 August 2025 |
| Version creation reason        |                |

### Trial information

#### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 213560 |
|-----------------------|--------|

#### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT04908865 |
| WHO universal trial number (UTN)   | -           |

Notes:

### Sponsors

|                              |                                                                                  |
|------------------------------|----------------------------------------------------------------------------------|
| Sponsor organisation name    | GlaxoSmithKline                                                                  |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS               |
| Public contact               | GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com |
| Scientific contact           | GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com |

Notes:

### Paediatric regulatory details

|                                                                      |     |
|----------------------------------------------------------------------|-----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No  |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No  |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

|                                                      |                   |
|------------------------------------------------------|-------------------|
| Analysis stage                                       | Final             |
| Date of interim/final analysis                       | 20 September 2024 |
| Is this the analysis of the primary completion data? | No                |
| Global end of trial reached?                         | Yes               |
| Global end of trial date                             | 13 August 2024    |
| Was the trial ended prematurely?                     | No                |

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the safety and efficacy of belimumab IV in Chinese pediatric participants with SLE.

Protection of trial subjects:

NA

Background therapy: -

Evidence for comparator: -

|                                                           |                 |
|-----------------------------------------------------------|-----------------|
| Actual start date of recruitment                          | 21 October 2021 |
| Long term follow-up planned                               | No              |
| Independent data monitoring committee (IDMC) involvement? | No              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |           |
|--------------------------------------|-----------|
| Country: Number of subjects enrolled | China: 67 |
| Worldwide total number of subjects   | 67        |
| EEA total number of subjects         | 0         |

Notes:

### Subjects enrolled per age group

|                                           |    |
|-------------------------------------------|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 0  |
| Children (2-11 years)                     | 16 |
| Adolescents (12-17 years)                 | 51 |
| Adults (18-64 years)                      | 0  |
| From 65 to 84 years                       | 0  |
| 85 years and over                         | 0  |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 67 participants were enrolled in the study.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Not applicable                 |
| Blinding used                | Not blinded                    |

### Arms

|           |           |
|-----------|-----------|
| Arm title | Belimumab |
|-----------|-----------|

Arm description:

Participants with active systemic lupus erythematosus (SLE) received belimumab at 10 milligrams per kilogram (mg/kg) body weight by intravenous (IV) infusion over a minimum of 1 hour on Days 0, 14, 28, and then every 28 days through Week 48 in combination with standard therapy.

|                                        |                 |
|----------------------------------------|-----------------|
| Arm type                               | Experimental    |
| Investigational medicinal product name | Belimumab       |
| Investigational medicinal product code |                 |
| Other name                             |                 |
| Pharmaceutical forms                   | Infusion        |
| Routes of administration               | Intravenous use |

Dosage and administration details:

10 milligrams per kilogram (mg/kg) on Days 0, 14, 28, and then every 28 days through Week 48

| Number of subjects in period 1  | Belimumab         |
|---------------------------------|-------------------|
| Started                         | 67                |
| Pharmacokinetic (PK) Population | 26 <sup>[1]</sup> |
| Completed                       | 59                |
| Not completed                   | 8                 |
| Adverse event, non-fatal        | 2                 |
| Lost to follow-up               | 1                 |
| Lack of efficacy                | 5                 |

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: PK population was added as a milestone because the study contains endpoints based on this population.

## Baseline characteristics

### Reporting groups

|                       |           |
|-----------------------|-----------|
| Reporting group title | Belimumab |
|-----------------------|-----------|

Reporting group description:

Participants with active systemic lupus erythematosus (SLE) received belimumab at 10 milligrams per kilogram (mg/kg) body weight by intravenous (IV) infusion over a minimum of 1 hour on Days 0, 14, 28, and then every 28 days through Week 48 in combination with standard therapy.

| Reporting group values                                | Belimumab | Total |  |
|-------------------------------------------------------|-----------|-------|--|
| Number of subjects                                    | 67        | 67    |  |
| Age categorical                                       |           |       |  |
| Units: Subjects                                       |           |       |  |
| In utero                                              | 0         | 0     |  |
| Preterm newborn infants<br>(gestational age < 37 wks) | 0         | 0     |  |
| Newborns (0-27 days)                                  | 0         | 0     |  |
| Infants and toddlers (28 days-23<br>months)           | 0         | 0     |  |
| Children (2-11 years)                                 | 16        | 16    |  |
| Adolescents (12-17 years)                             | 51        | 51    |  |
| Adults (18-64 years)                                  | 0         | 0     |  |
| From 65-84 years                                      | 0         | 0     |  |
| 85 years and over                                     | 0         | 0     |  |
| Age continuous                                        |           |       |  |
| Units: years                                          |           |       |  |
| arithmetic mean                                       | 13.0      |       |  |
| standard deviation                                    | ± 2.22    | -     |  |
| Sex: Female, Male                                     |           |       |  |
| Units: Participants                                   |           |       |  |
| Female                                                | 51        | 51    |  |
| Male                                                  | 16        | 16    |  |
| Race/Ethnicity, Customized                            |           |       |  |
| Units: Subjects                                       |           |       |  |
| Asian                                                 | 67        | 67    |  |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                                                                        |           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Reporting group title                                                                                                                                                                                                                                                                  | Belimumab |
| Reporting group description:                                                                                                                                                                                                                                                           |           |
| Participants with active systemic lupus erythematosus (SLE) received belimumab at 10 milligrams per kilogram (mg/kg) body weight by intravenous (IV) infusion over a minimum of 1 hour on Days 0, 14, 28, and then every 28 days through Week 48 in combination with standard therapy. |           |

### Primary: Number of Participants with Adverse Events of Special Interest (AESIs) Through Week 52

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Number of Participants with Adverse Events of Special Interest (AESIs) Through Week 52 <sup>[1]</sup> |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                       |
| An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AESIs included malignancies, post-infusion systemic or hypersensitivity reactions, infections (including serious infections of special interest), and depression (including mood disorders and anxiety), suicide, or self-injury. Infections of special interest included opportunistic infections (OI), herpes zoster (HZ), tuberculosis (TB), and sepsis. Number of participants with AESIs as identified by custom Medical Dictionary for Regulatory Activities (MedDRA) query has been reported. Intent-to-Treat (ITT) population consisted of all participants who received at least one dose of study treatment. |                                                                                                       |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Primary                                                                                               |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                       |
| Up to Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                       |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As per the study protocol, no formal hypothesis testing was planned in the study. Hence, no statistical analyses have been specified for this endpoint.

| End point values                        | Belimumab       |  |  |  |
|-----------------------------------------|-----------------|--|--|--|
| Subject group type                      | Reporting group |  |  |  |
| Number of subjects analysed             | 67              |  |  |  |
| Units: Participants                     |                 |  |  |  |
| All malignancies                        | 0               |  |  |  |
| Post-infusion systemic reactions (PISR) | 0               |  |  |  |
| All infections of special interest      | 2               |  |  |  |
| Depression/suicide/self-injury          | 0               |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Greater than Equal to ( $\geq$ ) 4 Points Reduction from Baseline to Week 52 in Safety of Estrogen in Lupus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Score

|                 |                                                                                                                                                                              |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants With Greater than Equal to ( $\geq$ ) 4 Points Reduction from Baseline to Week 52 in Safety of Estrogen in Lupus National Assessment - Systemic Lupus |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## End point description:

SELENA-SLEDAI score is cumulative and weighted index for assessing SLE disease activity in participants with SLE. It consists of 24 disease descriptors across 9 organ systems. Each descriptor is assigned a weighted score (8 descriptors with a weight of 8 each, 6 descriptors with a weight of 4 each, 7 descriptors with a weight of 2 each, and 3 descriptors with a weight of 1 each) which is added up if the descriptor is observed during a visit or within the preceding 10 days. Total score ranges from 0 (no disease activity) to 105 (all 24 descriptors present simultaneously). Higher score indicates a more significant degree of disease activity. Baseline was defined as latest pre-dose assessment with non-missing value, including those from unscheduled visits. Number of participants with decrease of  $\geq 4$  points in score at Week 52 compared to Baseline is presented. ITT population. One participant with Baseline SELENA-SLEDAI score below ( $<$ ) 4 was excluded.

## End point type

Primary

## End point timeframe:

Baseline (Day 0) and Week 52

## Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As per the study protocol, no formal hypothesis testing was planned in the study. Hence, no statistical analyses have been specified for this endpoint.

| End point values            | Belimumab       |  |  |  |
|-----------------------------|-----------------|--|--|--|
| Subject group type          | Reporting group |  |  |  |
| Number of subjects analysed | 66              |  |  |  |
| Units: Participants         | 44              |  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With AEs and Serious Adverse Events (SAEs) Through Week 52

## End point title

Number of Participants With AEs and Serious Adverse Events (SAEs) Through Week 52

## End point description:

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly, or other situations as per the medical or scientific judgment of the investigator. Number of participants with AEs and SAEs has been reported. ITT population consisted of all participants who received at least one dose of study treatment.

## End point type

Secondary

## End point timeframe:

Up to Week 52

|                             |                 |  |  |  |
|-----------------------------|-----------------|--|--|--|
| <b>End point values</b>     | Belimumab       |  |  |  |
| Subject group type          | Reporting group |  |  |  |
| Number of subjects analysed | 67              |  |  |  |
| Units: Participants         |                 |  |  |  |
| AEs                         | 56              |  |  |  |
| SAEs                        | 19              |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With $\geq 4$ Points Reduction from Baseline in SELENA-SLEDAI Score by Each Visit

|                 |                                                                                                              |
|-----------------|--------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants With $\geq 4$ Points Reduction from Baseline in SELENA-SLEDAI Score by Each Visit |
|-----------------|--------------------------------------------------------------------------------------------------------------|

End point description:

SELENA-SLEDAI score is used to assess SLE disease activity in participants with SLE. It consists of 24 disease descriptors across 9 organ systems. Each descriptor is assigned a weight (8 descriptors: each weighted 8; 6 descriptors: each weighted 4; 7 descriptors: each weighted 2; 3 descriptors: each weighted 1) which is summed if the descriptor is observed during a visit or within preceding 10 days. Total score ranges from 0 (no disease activity) to 105 (all 24 descriptors present together). Higher score means more significant degree of disease activity. Baseline was the latest pre-dose assessment with non-missing value, including those from unscheduled visits. ITT population. 1 participant with Baseline score  $< 4$  was excluded. All 66 participants served as denominator to calculate percentages at each visit. Due to rounding off at Week 52 (as no data was missing) and use of multiple imputation for missing data for all other visits, percentages may not yield whole participants.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 0) and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

|                                   |                 |  |  |  |
|-----------------------------------|-----------------|--|--|--|
| <b>End point values</b>           | Belimumab       |  |  |  |
| Subject group type                | Reporting group |  |  |  |
| Number of subjects analysed       | 66              |  |  |  |
| Units: Percentage of Participants |                 |  |  |  |
| number (not applicable)           |                 |  |  |  |
| Week 4                            | 39.8            |  |  |  |
| Week 8                            | 51.8            |  |  |  |
| Week 12                           | 68.9            |  |  |  |
| Week 16                           | 69.0            |  |  |  |
| Week 20                           | 65.4            |  |  |  |
| Week 24                           | 68.1            |  |  |  |
| Week 28                           | 65.7            |  |  |  |
| Week 32                           | 67.7            |  |  |  |
| Week 36                           | 69.1            |  |  |  |
| Week 40                           | 75.1            |  |  |  |
| Week 44                           | 74.2            |  |  |  |
| Week 48                           | 71.3            |  |  |  |
| Week 52                           | 66.7            |  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to Week 52 in Physician Global Assessment (PGA)

|                 |                                                                      |
|-----------------|----------------------------------------------------------------------|
| End point title | Change from Baseline to Week 52 in Physician Global Assessment (PGA) |
|-----------------|----------------------------------------------------------------------|

End point description:

The PGA is used to assess the participant's current disease activity by investigator. It is collected on a 10 centimeter (cm) visual analogue scale. The score ranges from 0 (no activity) to 3 (severe activity). Lower score means no disease activity, higher score means severe disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. ITT population consisted of all participants who received at least one dose of study treatment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 0) and Week 52

| End point values                     | Belimumab         |  |  |  |
|--------------------------------------|-------------------|--|--|--|
| Subject group type                   | Reporting group   |  |  |  |
| Number of subjects analysed          | 67                |  |  |  |
| Units: Scores on scale               |                   |  |  |  |
| arithmetic mean (standard deviation) | -0.931 (± 0.6046) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to Week 52 in Parent Global Assessment (ParentGA)

|                 |                                                                        |
|-----------------|------------------------------------------------------------------------|
| End point title | Change from Baseline to Week 52 in Parent Global Assessment (ParentGA) |
|-----------------|------------------------------------------------------------------------|

End point description:

The ParentGA is used to assess the participant's overall well-being at the moment rated on a 21-numbered circle visual analog scale by the parent. The score ranges from 0 (very well) to 10 (very poorly). Higher score indicates worse effect of the illness on the child. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. ITT population consisted of all participants who received at least one dose of study treatment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 0) and Week 52



|                                      |                      |  |  |  |
|--------------------------------------|----------------------|--|--|--|
| <b>End point values</b>              | Belimumab            |  |  |  |
| Subject group type                   | Reporting group      |  |  |  |
| Number of subjects analysed          | 67                   |  |  |  |
| Units: Scores on scale               |                      |  |  |  |
| arithmetic mean (standard deviation) | -2.71 ( $\pm$ 2.713) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Average Daily Prednisone Equivalent Dose at Week 52

|                 |                                                                             |
|-----------------|-----------------------------------------------------------------------------|
| End point title | Change from Baseline in Average Daily Prednisone Equivalent Dose at Week 52 |
|-----------------|-----------------------------------------------------------------------------|

End point description:

Average daily prednisone equivalent dose included all steroids taken. All steroid dosages were converted to prednisone equivalent in mg at each visit. Daily prednisone equivalent dose was calculated as follows: dose of steroid in mg multiplied by (\*) conversion factor \* frequency factor. Baseline was defined as latest pre-dose assessment with non-missing value, including those from unscheduled visits. Baseline average daily prednisone equivalent dose was sum of all prednisone doses over 7 consecutive days up to but not including Day 0 divided by 7. Average daily prednisone dose at Week 52 visit was sum of all prednisone doses over 7 consecutive days up to and including Week 52 visit divided by 7. Average daily prednisone equivalent dose was expressed in mg per day. ITT population included all participants who received at least 1 dose of study treatment. 'Number of Subjects Analyzed' included only those participants who were analyzed (i.e., contributed data reported in table).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 0) and Week 52

|                                      |                        |  |  |  |
|--------------------------------------|------------------------|--|--|--|
| <b>End point values</b>              | Belimumab              |  |  |  |
| Subject group type                   | Reporting group        |  |  |  |
| Number of subjects analysed          | 59                     |  |  |  |
| Units: milligrams per day            |                        |  |  |  |
| arithmetic mean (standard deviation) | -6.020 ( $\pm$ 9.2970) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to First Flare Over 52 Weeks

|                 |                                   |
|-----------------|-----------------------------------|
| End point title | Time to First Flare Over 52 Weeks |
|-----------------|-----------------------------------|

**End point description:**

SLE flare index (SFI) is used to categorize SLE flares as mild/moderate or severe. Mild/moderate SFI flare: SELENA-SLEDAI score increase of 3 to 12 (higher score - greater disease activity); SLE symptom development; prednisone dose increase (but not above [ $>$ ] 0.5 milligrams per kilogram per day [mg/kg/day]); non-steroidal anti-inflammatory drugs (NSAIDs)/hydroxychloroquine addition; or PGA score increase by  $\geq 1$ , but not to  $> 2.5$  (higher score - greater disease activity). Severe SFI flare: SELENA-SLEDAI score increase  $> 12$ ; onset or worsening of severe SLE symptoms; prednisone dose increase  $> 0.5$  mg/kg/day; introduction of potent immunosuppressants; hospitalization; or PGA score reaching  $\geq 2.5$ . Time to first SLE flare was number of days from treatment start date until the event. Time to first flare was defined as event date minus treatment start date plus 1. ITT population. 'Number of subjects analyzed' included participants with post-baseline SFI flare over 52 weeks.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Week 52

| End point values                      | Belimumab             |  |  |  |
|---------------------------------------|-----------------------|--|--|--|
| Subject group type                    | Reporting group       |  |  |  |
| Number of subjects analysed           | 50                    |  |  |  |
| Units: days                           |                       |  |  |  |
| median (inter-quartile range (Q1-Q3)) | 141.0 (58.0 to 333.0) |  |  |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Time to First Severe Flare Over 52 Weeks**

|                 |                                          |
|-----------------|------------------------------------------|
| End point title | Time to First Severe Flare Over 52 Weeks |
|-----------------|------------------------------------------|

**End point description:**

SFI is used to categorize SLE flares as mild/moderate or severe. Severe SFI flare: SELENA-SLEDAI score increase  $> 12$ ; onset or worsening of severe SLE symptoms; prednisone dose increase  $> 0.5$  mg/kg/day; introduction of potent immunosuppressants; hospitalization; or PGA score reaching  $\geq 2.5$ . Time to first SLE flare was number of days from treatment start date until the event. Time to first flare was defined as event date minus treatment start date plus 1. ITT population. 'Number of subjects analyzed' included participants with post-baseline severe SFI flare over 52 weeks. '99999' indicates that the median time and/or interquartile range could not be estimated due to low number of events in the participants.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Week 52

| End point values                      | Belimumab              |  |  |  |
|---------------------------------------|------------------------|--|--|--|
| Subject group type                    | Reporting group        |  |  |  |
| Number of subjects analysed           | 18                     |  |  |  |
| Units: days                           |                        |  |  |  |
| median (inter-quartile range (Q1-Q3)) | 99999 (289.0 to 99999) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Median Belimumab Concentration Levels at Day 0, 7, and 14 Days Post First Dose, and Pre-infusion and Post-infusion at Day 84

|                 |                                                                                                                              |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|
| End point title | Median Belimumab Concentration Levels at Day 0, 7, and 14 Days Post First Dose, and Pre-infusion and Post-infusion at Day 84 |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|

#### End point description:

Blood samples were collected at indicated time points for measurement of plasma concentrations of belimumab. Pharmacokinetic (PK) population consisted of all the participants who received at least one dose of study treatment and for whom at least one post belimumab treatment PK sample was obtained and analyzed. 'Number of subjects analyzed' included only those participants who were analyzed (i.e., contributed data reported in table). 'n' indicates participants evaluable for specified time points.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

#### End point timeframe:

Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

| End point values                 | Belimumab                 |  |  |  |
|----------------------------------|---------------------------|--|--|--|
| Subject group type               | Reporting group           |  |  |  |
| Number of subjects analysed      | 26                        |  |  |  |
| Units: Micrograms per milliliter |                           |  |  |  |
| median (full range (min-max))    |                           |  |  |  |
| Day 0 (n=24)                     | 197.12 (141.93 to 257.37) |  |  |  |
| Day 7 (n=26)                     | 71.36 (35.95 to 100.59)   |  |  |  |
| Day 14 (n=26)                    | 37.86 (14.59 to 74.17)    |  |  |  |
| Day 84, pre-infusion (n=25)      | 28.24 (2.35 to 89.07)     |  |  |  |
| Day 84, post-infusion (n=25)     | 238.57 (139.19 to 357.03) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Apparent Total Clearance of Belimumab

|                 |                                       |
|-----------------|---------------------------------------|
| End point title | Apparent Total Clearance of Belimumab |
|-----------------|---------------------------------------|

End point description:

Blood samples were collected at indicated time points for PK analysis of belimumab. PK population consisted of all the participants who received at least one dose of study treatment and for whom at least one post belimumab treatment PK sample was obtained and analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

|                                                     |                       |  |  |  |
|-----------------------------------------------------|-----------------------|--|--|--|
| <b>End point values</b>                             | Belimumab             |  |  |  |
| Subject group type                                  | Reporting group       |  |  |  |
| Number of subjects analysed                         | 26                    |  |  |  |
| Units: Milliliters per day                          |                       |  |  |  |
| geometric mean (geometric coefficient of variation) | 155.39 ( $\pm$ 32.07) |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Volume of Distribution of Belimumab

|                 |                                     |
|-----------------|-------------------------------------|
| End point title | Volume of Distribution of Belimumab |
|-----------------|-------------------------------------|

End point description:

Blood samples were collected at indicated time points for PK analysis of belimumab. PK population consisted of all the participants who received at least one dose of study treatment and for whom at least one post belimumab treatment PK sample was obtained and analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

|                                                     |                        |  |  |  |
|-----------------------------------------------------|------------------------|--|--|--|
| <b>End point values</b>                             | Belimumab              |  |  |  |
| Subject group type                                  | Reporting group        |  |  |  |
| Number of subjects analysed                         | 26                     |  |  |  |
| Units: Milliliters                                  |                        |  |  |  |
| geometric mean (geometric coefficient of variation) | 3670.31 ( $\pm$ 23.66) |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Terminal Half-life (t<sub>1/2</sub>) of Belimumab

|                 |                                                     |
|-----------------|-----------------------------------------------------|
| End point title | Terminal Half-life (t <sub>1/2</sub> ) of Belimumab |
|-----------------|-----------------------------------------------------|

End point description:

Blood samples were collected at indicated time points for PK analysis of belimumab. PK population consisted of all the participants who received at least one dose of study treatment and for whom at least one post belimumab treatment PK sample was obtained and analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

|                                                     |                      |  |  |  |
|-----------------------------------------------------|----------------------|--|--|--|
| <b>End point values</b>                             | Belimumab            |  |  |  |
| Subject group type                                  | Reporting group      |  |  |  |
| Number of subjects analysed                         | 26                   |  |  |  |
| Units: Days                                         |                      |  |  |  |
| geometric mean (geometric coefficient of variation) | 17.43 ( $\pm$ 30.51) |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum Plasma Concentration (C<sub>max</sub>) of Belimumab at Steady State

|                 |                                                                               |
|-----------------|-------------------------------------------------------------------------------|
| End point title | Maximum Plasma Concentration (C <sub>max</sub> ) of Belimumab at Steady State |
|-----------------|-------------------------------------------------------------------------------|

End point description:

Blood samples were collected at indicated time points for PK analysis of belimumab. PK population consisted of all the participants who received at least one dose of study treatment and for whom at least one post belimumab treatment PK sample was obtained and analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

|                                                     |                       |  |  |  |
|-----------------------------------------------------|-----------------------|--|--|--|
| <b>End point values</b>                             | Belimumab             |  |  |  |
| Subject group type                                  | Reporting group       |  |  |  |
| Number of subjects analysed                         | 26                    |  |  |  |
| Units: Micrograms per milliliter                    |                       |  |  |  |
| geometric mean (geometric coefficient of variation) | 219.87 ( $\pm$ 18.13) |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Minimum Plasma Concentration Reached Prior to Administration of Next Dose (C<sub>min</sub>) of Belimumab at Steady State

|                                                                                                                                                                                                                                                                               |                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                               | Minimum Plasma Concentration Reached Prior to Administration of Next Dose (Cmin) of Belimumab at Steady State |
| End point description:                                                                                                                                                                                                                                                        |                                                                                                               |
| Blood samples were collected at indicated time points for PK analysis of belimumab. PK population consisted of all the participants who received at least one dose of study treatment and for whom at least one post belimumab treatment PK sample was obtained and analyzed. |                                                                                                               |
| End point type                                                                                                                                                                                                                                                                | Secondary                                                                                                     |
| End point timeframe:                                                                                                                                                                                                                                                          |                                                                                                               |
| Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84                                                                                                                                                                                          |                                                                                                               |

|                                                     |                 |  |  |  |
|-----------------------------------------------------|-----------------|--|--|--|
| <b>End point values</b>                             | Belimumab       |  |  |  |
| Subject group type                                  | Reporting group |  |  |  |
| Number of subjects analysed                         | 26              |  |  |  |
| Units: Micrograms per milliliter                    |                 |  |  |  |
| geometric mean (geometric coefficient of variation) | 36.92 (± 62.14) |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Average Plasma Concentration (Cavg) of Belimumab at Steady State

|                                                                                                                                                                                                                                                                               |                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                               | Average Plasma Concentration (Cavg) of Belimumab at Steady State |
| End point description:                                                                                                                                                                                                                                                        |                                                                  |
| Blood samples were collected at indicated time points for PK analysis of belimumab. PK population consisted of all the participants who received at least one dose of study treatment and for whom at least one post belimumab treatment PK sample was obtained and analyzed. |                                                                  |
| End point type                                                                                                                                                                                                                                                                | Secondary                                                        |
| End point timeframe:                                                                                                                                                                                                                                                          |                                                                  |
| Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84                                                                                                                                                                                          |                                                                  |

|                                                     |                 |  |  |  |
|-----------------------------------------------------|-----------------|--|--|--|
| <b>End point values</b>                             | Belimumab       |  |  |  |
| Subject group type                                  | Reporting group |  |  |  |
| Number of subjects analysed                         | 26              |  |  |  |
| Units: Micrograms per milliliter                    |                 |  |  |  |
| geometric mean (geometric coefficient of variation) | 75.09 (± 34.37) |  |  |  |

### Statistical analyses

No statistical analyses for this end point

---

**Secondary: Area Under the Concentration Curve (AUC) of Belimumab at Steady State**

---

|                 |                                                                       |
|-----------------|-----------------------------------------------------------------------|
| End point title | Area Under the Concentration Curve (AUC) of Belimumab at Steady State |
|-----------------|-----------------------------------------------------------------------|

---

End point description:

Blood samples were collected at indicated time points for PK analysis of belimumab. PK population consisted of all the participants who received at least one dose of study treatment and for whom at least one post belimumab treatment PK sample was obtained and analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

End point timeframe:

Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

---

|                                                     |                        |  |  |  |
|-----------------------------------------------------|------------------------|--|--|--|
| <b>End point values</b>                             | Belimumab              |  |  |  |
| Subject group type                                  | Reporting group        |  |  |  |
| Number of subjects analysed                         | 26                     |  |  |  |
| Units: Days*micrograms per milliliter               |                        |  |  |  |
| geometric mean (geometric coefficient of variation) | 2102.65 ( $\pm$ 34.37) |  |  |  |

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All-cause mortality, SAEs, and non-serious adverse events (non-SAEs) were collected from the start of the study intervention (Day 0) up to the post-treatment follow-up visit at Week 64

Adverse event reporting additional description:

All-cause mortality, SAEs, and non-SAEs were reported for ITT population that comprised of all participants who received at least 1 dose of study treatment.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 27.0 |
|--------------------|------|

### Reporting groups

|                       |           |
|-----------------------|-----------|
| Reporting group title | Belimumab |
|-----------------------|-----------|

Reporting group description:

Participants with active SLE received belimumab at 10 mg/kg body weight by IV infusion over a minimum of 1 hour on Days 0, 14, 28, and then every 28 days through Week 48 in combination with standard therapy.

| Serious adverse events                            | Belimumab        |  |  |
|---------------------------------------------------|------------------|--|--|
| Total subjects affected by serious adverse events |                  |  |  |
| subjects affected / exposed                       | 20 / 67 (29.85%) |  |  |
| number of deaths (all causes)                     | 0                |  |  |
| number of deaths resulting from adverse events    | 0                |  |  |
| Cardiac disorders                                 |                  |  |  |
| Myocarditis                                       |                  |  |  |
| subjects affected / exposed                       | 1 / 67 (1.49%)   |  |  |
| occurrences causally related to treatment / all   | 0 / 1            |  |  |
| deaths causally related to treatment / all        | 0 / 0            |  |  |
| Nervous system disorders                          |                  |  |  |
| Cerebral infarction                               |                  |  |  |
| subjects affected / exposed                       | 1 / 67 (1.49%)   |  |  |
| occurrences causally related to treatment / all   | 1 / 1            |  |  |
| deaths causally related to treatment / all        | 0 / 0            |  |  |
| Headache                                          |                  |  |  |
| subjects affected / exposed                       | 2 / 67 (2.99%)   |  |  |
| occurrences causally related to treatment / all   | 1 / 2            |  |  |
| deaths causally related to treatment / all        | 0 / 0            |  |  |
| Neuromyelitis optica spectrum disorder            |                  |  |  |



|                                                      |                |  |  |
|------------------------------------------------------|----------------|--|--|
| subjects affected / exposed                          | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| General disorders and administration site conditions |                |  |  |
| Pyrexia                                              |                |  |  |
| subjects affected / exposed                          | 2 / 67 (2.99%) |  |  |
| occurrences causally related to treatment / all      | 0 / 2          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Blood and lymphatic system disorders                 |                |  |  |
| Thrombocytopenia                                     |                |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all      | 2 / 2          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Immune system disorders                              |                |  |  |
| Hypogammaglobulinaemia                               |                |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Eye disorders                                        |                |  |  |
| Eyelid oedema                                        |                |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Gastrointestinal disorders                           |                |  |  |
| Gastrointestinal haemorrhage                         |                |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Pancreatitis necrotising                             |                |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Respiratory, thoracic and mediastinal disorders      |                |  |  |
| Pulmonary arterial hypertension                      |                |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Interstitial lung disease                       |                |  |  |
| subjects affected / exposed                     | 2 / 67 (2.99%) |  |  |
| occurrences causally related to treatment / all | 0 / 2          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Hepatobiliary disorders                         |                |  |  |
| Hepatic function abnormal                       |                |  |  |
| subjects affected / exposed                     | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all | 1 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Skin and subcutaneous tissue disorders          |                |  |  |
| Alopecia                                        |                |  |  |
| subjects affected / exposed                     | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Rash                                            |                |  |  |
| subjects affected / exposed                     | 4 / 67 (5.97%) |  |  |
| occurrences causally related to treatment / all | 0 / 4          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Musculoskeletal and connective tissue disorders |                |  |  |
| Systemic lupus erythematosus                    |                |  |  |
| subjects affected / exposed                     | 3 / 67 (4.48%) |  |  |
| occurrences causally related to treatment / all | 0 / 4          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Infections and infestations                     |                |  |  |
| H1N1 influenza                                  |                |  |  |
| subjects affected / exposed                     | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Gastroenteritis                                 |                |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| COVID-19                                        |                |  |  |
| subjects affected / exposed                     | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Bronchitis                                      |                |  |  |
| subjects affected / exposed                     | 3 / 67 (4.48%) |  |  |
| occurrences causally related to treatment / all | 1 / 3          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Pneumonia                                       |                |  |  |
| subjects affected / exposed                     | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all | 1 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Upper respiratory tract infection               |                |  |  |
| subjects affected / exposed                     | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all | 1 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Urinary tract infection                         |                |  |  |
| subjects affected / exposed                     | 1 / 67 (1.49%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |

Frequency threshold for reporting non-serious adverse events: 0 %

|                                                       |                  |  |  |
|-------------------------------------------------------|------------------|--|--|
| <b>Non-serious adverse events</b>                     | Belimumab        |  |  |
| Total subjects affected by non-serious adverse events |                  |  |  |
| subjects affected / exposed                           | 57 / 67 (85.07%) |  |  |
| Vascular disorders                                    |                  |  |  |
| Hypertension                                          |                  |  |  |
| subjects affected / exposed                           | 1 / 67 (1.49%)   |  |  |
| occurrences (all)                                     | 1                |  |  |
| Venous thrombosis                                     |                  |  |  |

|                                                      |                 |  |  |
|------------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                          | 1 / 67 (1.49%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Endocrine hypertension                               |                 |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| General disorders and administration site conditions |                 |  |  |
| Pyrexia                                              |                 |  |  |
| subjects affected / exposed                          | 7 / 67 (10.45%) |  |  |
| occurrences (all)                                    | 9               |  |  |
| Chest pain                                           |                 |  |  |
| subjects affected / exposed                          | 2 / 67 (2.99%)  |  |  |
| occurrences (all)                                    | 2               |  |  |
| Face oedema                                          |                 |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Peripheral swelling                                  |                 |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Fatigue                                              |                 |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Immune system disorders                              |                 |  |  |
| Drug hypersensitivity                                |                 |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Hypogammaglobulinaemia                               |                 |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Respiratory, thoracic and mediastinal disorders      |                 |  |  |
| Cough                                                |                 |  |  |
| subjects affected / exposed                          | 9 / 67 (13.43%) |  |  |
| occurrences (all)                                    | 13              |  |  |
| Rhinitis allergic                                    |                 |  |  |
| subjects affected / exposed                          | 1 / 67 (1.49%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Epistaxis                                            |                 |  |  |

|                                  |                |  |  |
|----------------------------------|----------------|--|--|
| subjects affected / exposed      | 1 / 67 (1.49%) |  |  |
| occurrences (all)                | 1              |  |  |
| Oropharyngeal pain               |                |  |  |
| subjects affected / exposed      | 1 / 67 (1.49%) |  |  |
| occurrences (all)                | 1              |  |  |
| Productive cough                 |                |  |  |
| subjects affected / exposed      | 1 / 67 (1.49%) |  |  |
| occurrences (all)                | 2              |  |  |
| Dyspnoea                         |                |  |  |
| subjects affected / exposed      | 1 / 67 (1.49%) |  |  |
| occurrences (all)                | 1              |  |  |
| Investigations                   |                |  |  |
| Lymphocyte count decreased       |                |  |  |
| subjects affected / exposed      | 5 / 67 (7.46%) |  |  |
| occurrences (all)                | 9              |  |  |
| White blood cell count decreased |                |  |  |
| subjects affected / exposed      | 4 / 67 (5.97%) |  |  |
| occurrences (all)                | 11             |  |  |
| Intraocular pressure increased   |                |  |  |
| subjects affected / exposed      | 3 / 67 (4.48%) |  |  |
| occurrences (all)                | 3              |  |  |
| Neutrophil count increased       |                |  |  |
| subjects affected / exposed      | 2 / 67 (2.99%) |  |  |
| occurrences (all)                | 3              |  |  |
| Blood bilirubin increased        |                |  |  |
| subjects affected / exposed      | 1 / 67 (1.49%) |  |  |
| occurrences (all)                | 1              |  |  |
| Blood immunoglobulin M decreased |                |  |  |
| subjects affected / exposed      | 1 / 67 (1.49%) |  |  |
| occurrences (all)                | 1              |  |  |
| Blood phosphorus decreased       |                |  |  |
| subjects affected / exposed      | 1 / 67 (1.49%) |  |  |
| occurrences (all)                | 1              |  |  |
| CD19 lymphocytes decreased       |                |  |  |
| subjects affected / exposed      | 1 / 67 (1.49%) |  |  |
| occurrences (all)                | 1              |  |  |

|                                                                                      |                     |  |  |
|--------------------------------------------------------------------------------------|---------------------|--|--|
| Neutrophil count decreased<br>subjects affected / exposed<br>occurrences (all)       | 1 / 67 (1.49%)<br>1 |  |  |
| Reticulocyte count increased<br>subjects affected / exposed<br>occurrences (all)     | 1 / 67 (1.49%)<br>1 |  |  |
| White blood cell count increased<br>subjects affected / exposed<br>occurrences (all) | 1 / 67 (1.49%)<br>2 |  |  |
| Bone density decreased<br>subjects affected / exposed<br>occurrences (all)           | 1 / 67 (1.49%)<br>1 |  |  |
| Injury, poisoning and procedural complications                                       |                     |  |  |
| Animal bite<br>subjects affected / exposed<br>occurrences (all)                      | 1 / 67 (1.49%)<br>1 |  |  |
| Arthropod bite<br>subjects affected / exposed<br>occurrences (all)                   | 1 / 67 (1.49%)<br>1 |  |  |
| Contusion<br>subjects affected / exposed<br>occurrences (all)                        | 1 / 67 (1.49%)<br>1 |  |  |
| Ligament sprain<br>subjects affected / exposed<br>occurrences (all)                  | 1 / 67 (1.49%)<br>1 |  |  |
| Hand fracture<br>subjects affected / exposed<br>occurrences (all)                    | 1 / 67 (1.49%)<br>1 |  |  |
| Cardiac disorders                                                                    |                     |  |  |
| Sinus bradycardia<br>subjects affected / exposed<br>occurrences (all)                | 1 / 67 (1.49%)<br>1 |  |  |
| Arrhythmia<br>subjects affected / exposed<br>occurrences (all)                       | 1 / 67 (1.49%)<br>1 |  |  |
| Myocardial injury                                                                    |                     |  |  |

|                                      |                |  |  |
|--------------------------------------|----------------|--|--|
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Pericardial effusion                 |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Tachycardia                          |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Nervous system disorders             |                |  |  |
| Headache                             |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Seizure                              |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Blood and lymphatic system disorders |                |  |  |
| Anaemia                              |                |  |  |
| subjects affected / exposed          | 3 / 67 (4.48%) |  |  |
| occurrences (all)                    | 3              |  |  |
| Leukocytosis                         |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Neutropenia                          |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Polycythaemia                        |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Iron deficiency anaemia              |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Ear and labyrinth disorders          |                |  |  |
| Cerumen impaction                    |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Eye disorders                        |                |  |  |

|                                      |                |  |  |
|--------------------------------------|----------------|--|--|
| Eyelid oedema                        |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Xerophthalmia                        |                |  |  |
| subjects affected / exposed          | 2 / 67 (2.99%) |  |  |
| occurrences (all)                    | 2              |  |  |
| Conjunctivitis allergic              |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Ocular hypertension                  |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Retinal haemorrhage                  |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Gastrointestinal disorders           |                |  |  |
| Gastritis                            |                |  |  |
| subjects affected / exposed          | 3 / 67 (4.48%) |  |  |
| occurrences (all)                    | 3              |  |  |
| Functional gastrointestinal disorder |                |  |  |
| subjects affected / exposed          | 2 / 67 (2.99%) |  |  |
| occurrences (all)                    | 2              |  |  |
| Mouth ulceration                     |                |  |  |
| subjects affected / exposed          | 2 / 67 (2.99%) |  |  |
| occurrences (all)                    | 2              |  |  |
| Abdominal discomfort                 |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Abdominal pain                       |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Faeces discoloured                   |                |  |  |
| subjects affected / exposed          | 1 / 67 (1.49%) |  |  |
| occurrences (all)                    | 1              |  |  |
| Cheilitis                            |                |  |  |



|                             |                 |  |  |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Constipation                |                 |  |  |
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Diarrhoea                   |                 |  |  |
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 2               |  |  |
| Dyspepsia                   |                 |  |  |
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Anal fissure                |                 |  |  |
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Gastrointestinal disorder   |                 |  |  |
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Pancreatic pseudocyst       |                 |  |  |
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Pancreatitis acute          |                 |  |  |
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Hepatobiliary disorders     |                 |  |  |
| Hepatic function abnormal   |                 |  |  |
| subjects affected / exposed | 9 / 67 (13.43%) |  |  |
| occurrences (all)           | 13              |  |  |
| Cholestasis                 |                 |  |  |
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Hepatic steatosis           |                 |  |  |
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Hepatomegaly                |                 |  |  |
| subjects affected / exposed | 1 / 67 (1.49%)  |  |  |
| occurrences (all)           | 1               |  |  |

|                                                                                                                   |                     |  |  |
|-------------------------------------------------------------------------------------------------------------------|---------------------|--|--|
| Hepatic lesion<br>subjects affected / exposed<br>occurrences (all)                                                | 1 / 67 (1.49%)<br>1 |  |  |
| Skin and subcutaneous tissue disorders<br>Rash<br>subjects affected / exposed<br>occurrences (all)                | 4 / 67 (5.97%)<br>4 |  |  |
| Alopecia<br>subjects affected / exposed<br>occurrences (all)                                                      | 2 / 67 (2.99%)<br>2 |  |  |
| Dermatitis allergic<br>subjects affected / exposed<br>occurrences (all)                                           | 2 / 67 (2.99%)<br>2 |  |  |
| Acne<br>subjects affected / exposed<br>occurrences (all)                                                          | 1 / 67 (1.49%)<br>1 |  |  |
| Cutaneous vasculitis<br>subjects affected / exposed<br>occurrences (all)                                          | 1 / 67 (1.49%)<br>1 |  |  |
| Urticaria<br>subjects affected / exposed<br>occurrences (all)                                                     | 1 / 67 (1.49%)<br>1 |  |  |
| Renal and urinary disorders<br>Renal failure<br>subjects affected / exposed<br>occurrences (all)                  | 1 / 67 (1.49%)<br>1 |  |  |
| Endocrine disorders<br>Autoimmune thyroiditis<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 67 (1.49%)<br>1 |  |  |
| Musculoskeletal and connective tissue disorders<br>Arthralgia<br>subjects affected / exposed<br>occurrences (all) | 1 / 67 (1.49%)<br>1 |  |  |
| Arthritis                                                                                                         |                     |  |  |

|                                   |                  |  |  |
|-----------------------------------|------------------|--|--|
| subjects affected / exposed       | 1 / 67 (1.49%)   |  |  |
| occurrences (all)                 | 1                |  |  |
| Back pain                         |                  |  |  |
| subjects affected / exposed       | 1 / 67 (1.49%)   |  |  |
| occurrences (all)                 | 1                |  |  |
| Osteonecrosis                     |                  |  |  |
| subjects affected / exposed       | 1 / 67 (1.49%)   |  |  |
| occurrences (all)                 | 1                |  |  |
| Infections and infestations       |                  |  |  |
| Bronchitis                        |                  |  |  |
| subjects affected / exposed       | 4 / 67 (5.97%)   |  |  |
| occurrences (all)                 | 5                |  |  |
| COVID-19                          |                  |  |  |
| subjects affected / exposed       | 9 / 67 (13.43%)  |  |  |
| occurrences (all)                 | 9                |  |  |
| Upper respiratory tract infection |                  |  |  |
| subjects affected / exposed       | 31 / 67 (46.27%) |  |  |
| occurrences (all)                 | 63               |  |  |
| Coronavirus pneumonia             |                  |  |  |
| subjects affected / exposed       | 11 / 67 (16.42%) |  |  |
| occurrences (all)                 | 11               |  |  |
| Infection                         |                  |  |  |
| subjects affected / exposed       | 2 / 67 (2.99%)   |  |  |
| occurrences (all)                 | 2                |  |  |
| Conjunctivitis                    |                  |  |  |
| subjects affected / exposed       | 2 / 67 (2.99%)   |  |  |
| occurrences (all)                 | 2                |  |  |
| Gastroenteritis                   |                  |  |  |
| subjects affected / exposed       | 3 / 67 (4.48%)   |  |  |
| occurrences (all)                 | 3                |  |  |
| Respiratory tract infection       |                  |  |  |
| subjects affected / exposed       | 2 / 67 (2.99%)   |  |  |
| occurrences (all)                 | 2                |  |  |
| Influenza                         |                  |  |  |
| subjects affected / exposed       | 2 / 67 (2.99%)   |  |  |
| occurrences (all)                 | 2                |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| Oral candidiasis            |                |  |  |
| subjects affected / exposed | 2 / 67 (2.99%) |  |  |
| occurrences (all)           | 2              |  |  |
| Pneumonia                   |                |  |  |
| subjects affected / exposed | 2 / 67 (2.99%) |  |  |
| occurrences (all)           | 2              |  |  |
| Tinea versicolour           |                |  |  |
| subjects affected / exposed | 2 / 67 (2.99%) |  |  |
| occurrences (all)           | 3              |  |  |
| Herpangina                  |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Helicobacter infection      |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Urinary tract infection     |                |  |  |
| subjects affected / exposed | 2 / 67 (2.99%) |  |  |
| occurrences (all)           | 2              |  |  |
| Abscess soft tissue         |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Adenovirus infection        |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Gingivitis                  |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Sinusitis                   |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Tinea pedis                 |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Mumps                       |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |

|                                         |                |  |  |
|-----------------------------------------|----------------|--|--|
| Nasopharyngitis                         |                |  |  |
| subjects affected / exposed             | 1 / 67 (1.49%) |  |  |
| occurrences (all)                       | 1              |  |  |
| Oral herpes                             |                |  |  |
| subjects affected / exposed             | 1 / 67 (1.49%) |  |  |
| occurrences (all)                       | 1              |  |  |
| Otitis media                            |                |  |  |
| subjects affected / exposed             | 1 / 67 (1.49%) |  |  |
| occurrences (all)                       | 1              |  |  |
| Pharyngitis                             |                |  |  |
| subjects affected / exposed             | 1 / 67 (1.49%) |  |  |
| occurrences (all)                       | 1              |  |  |
| Rhinovirus infection                    |                |  |  |
| subjects affected / exposed             | 1 / 67 (1.49%) |  |  |
| occurrences (all)                       | 1              |  |  |
| Sepsis                                  |                |  |  |
| subjects affected / exposed             | 1 / 67 (1.49%) |  |  |
| occurrences (all)                       | 1              |  |  |
| Varicella                               |                |  |  |
| subjects affected / exposed             | 1 / 67 (1.49%) |  |  |
| occurrences (all)                       | 1              |  |  |
| Viral infection                         |                |  |  |
| subjects affected / exposed             | 1 / 67 (1.49%) |  |  |
| occurrences (all)                       | 1              |  |  |
| Viral upper respiratory tract infection |                |  |  |
| subjects affected / exposed             | 1 / 67 (1.49%) |  |  |
| occurrences (all)                       | 1              |  |  |
| Gastroenteritis viral                   |                |  |  |
| subjects affected / exposed             | 1 / 67 (1.49%) |  |  |
| occurrences (all)                       | 2              |  |  |
| Metabolism and nutrition disorders      |                |  |  |
| Hypokalaemia                            |                |  |  |
| subjects affected / exposed             | 3 / 67 (4.48%) |  |  |
| occurrences (all)                       | 4              |  |  |
| Hypoalbuminaemia                        |                |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Hyperglycaemia              |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Hyperlipidaemia             |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Hypertriglyceridaemia       |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Hyperuricaemia              |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Hypercholesterolaemia       |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Hypocalcaemia               |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Hypomagnesaemia             |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 2              |  |  |
| Hypophosphataemia           |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |
| Hypoproteinaemia            |                |  |  |
| subjects affected / exposed | 1 / 67 (1.49%) |  |  |
| occurrences (all)           | 1              |  |  |

**More information**

**Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? Yes

| Date            | Amendment            |
|-----------------|----------------------|
| 29 January 2021 | Protocol Amendment 1 |
| 03 June 2022    | Protocol Amendment 2 |
| 02 January 2023 | Protocol Amendment 3 |

Notes:

---

**Interruptions (globally)**

Were there any global interruptions to the trial? No

**Limitations and caveats**

None reported